Sabela Bobillo

1.2k total citations
39 papers, 437 citations indexed

About

Sabela Bobillo is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Sabela Bobillo has authored 39 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pathology and Forensic Medicine, 18 papers in Genetics and 18 papers in Oncology. Recurrent topics in Sabela Bobillo's work include Lymphoma Diagnosis and Treatment (28 papers), CAR-T cell therapy research (12 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Sabela Bobillo is often cited by papers focused on Lymphoma Diagnosis and Treatment (28 papers), CAR-T cell therapy research (12 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Sabela Bobillo collaborates with scholars based in Spain, United States and United Kingdom. Sabela Bobillo's co-authors include Francesc Bosch, Pau Abrisqueta, Kate Cwynarski, Josep Castellví, Cecilia Carpio, Andrés J.M. Ferreri, Marta Crespo, Jahanzaib Khwaja, Juan C. Nieto and Marc Simó and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sabela Bobillo

35 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sabela Bobillo Spain 11 271 206 121 114 64 39 437
Juan Pablo Alderuccio United States 13 538 2.0× 487 2.4× 159 1.3× 155 1.4× 60 0.9× 79 749
Jordina Rovira Spain 8 227 0.8× 137 0.7× 89 0.7× 59 0.5× 33 0.5× 9 310
Iván Dlouhy Spain 12 437 1.6× 311 1.5× 130 1.1× 71 0.6× 99 1.5× 26 557
Emmanuelle Nicolas‐Virelizier France 13 424 1.6× 285 1.4× 195 1.6× 176 1.5× 54 0.8× 58 585
Haiwen Huang China 11 203 0.7× 234 1.1× 122 1.0× 36 0.3× 154 2.4× 43 491
Gottfried von Keudell United States 13 293 1.1× 243 1.2× 151 1.2× 40 0.4× 179 2.8× 46 560
Catherine Chassagne‐Clément France 13 282 1.0× 145 0.7× 119 1.0× 90 0.8× 64 1.0× 44 410
Patti Cohen United States 9 388 1.4× 246 1.2× 151 1.2× 61 0.5× 19 0.3× 10 543
Kaija Vasala Finland 14 156 0.6× 251 1.2× 64 0.5× 63 0.6× 92 1.4× 27 483

Countries citing papers authored by Sabela Bobillo

Since Specialization
Citations

This map shows the geographic impact of Sabela Bobillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabela Bobillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabela Bobillo more than expected).

Fields of papers citing papers by Sabela Bobillo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabela Bobillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabela Bobillo. The network helps show where Sabela Bobillo may publish in the future.

Co-authorship network of co-authors of Sabela Bobillo

This figure shows the co-authorship network connecting the top 25 collaborators of Sabela Bobillo. A scholar is included among the top collaborators of Sabela Bobillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabela Bobillo. Sabela Bobillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vitolo, Umberto, Michele Merli, Lalita Norasetthada, et al.. (2024). Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).. Journal of Clinical Oncology. 42(16_suppl). TPS7094–TPS7094. 2 indexed citations
2.
Ghione, Paola, M. Lia Palomba, Eve H. Limbrick‐Oldfield, et al.. (2024). A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24(5). e191–e195.e6.
3.
Jiménez, Moraima, Alba Cabirta, Isabel Ruíz-Camps, et al.. (2023). Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders. Hematological Oncology. 41(S2). 607–609. 1 indexed citations
4.
5.
Ligero, Marta, Marc Simó, Cecilia Carpio, et al.. (2023). PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma. SHILAP Revista de lepidopterología. 4(4). 1081–1088. 7 indexed citations
6.
Abrisqueta, Pau, Daniel Medina, Guillermo Villacampa, et al.. (2022). A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Advances. 6(21). 5763–5773. 2 indexed citations
7.
Ghione, Paola, M. Lia Palomba, Anik R. Patel, et al.. (2022). Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 140(8). 851–860. 35 indexed citations
8.
Bobillo, Sabela, Jahanzaib Khwaja, Andrés J.M. Ferreri, & Kate Cwynarski. (2022). Prevention and management of secondary central nervous system lymphoma. Haematologica. 108(3). 673–689. 34 indexed citations
9.
Ghione, Paola, M. Lia Palomba, Hervé Ghesquières, et al.. (2022). Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 108(3). 822–832. 21 indexed citations
10.
Tazón‐Vega, Bárbara, Pau Abrisqueta, Juan C. Nieto, et al.. (2021). Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomarker Research. 9(1). 37–37. 5 indexed citations
11.
Iacoboni, Gloria, Marc Simó, Guillermo Villacampa, et al.. (2021). Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology. 100(9). 2303–2310. 41 indexed citations
12.
Bobillo, Sabela, Juan C. Nieto, & Pere Barba. (2021). Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. Bone Marrow Transplantation. 56(8). 1784–1793. 5 indexed citations
13.
Jiménez, Moraima, Sabela Bobillo, Alba Cabirta, et al.. (2020). Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Blood. 136(Supplement 1). 14–16. 2 indexed citations
14.
Bobillo, Sabela, Carlos Palacio, Pau Abrisqueta, et al.. (2020). Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. Journal of Neuro-Oncology. 149(1). 13–25. 22 indexed citations
15.
Bobillo, Sabela, Marta Crespo, Laura Escudero, et al.. (2020). Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 106(2). 513–521. 86 indexed citations
16.
17.
Gallur, Laura, Elisa Roldán, Fernando Martínez‐Valle, et al.. (2018). Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Annals of Hematology. 97(8). 1349–1356. 32 indexed citations
18.
Bobillo, Sabela, Pau Abrisqueta, Blanca Sánchez‐González, et al.. (2018). Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series. Annals of Hematology. 97(12). 2417–2424. 6 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juan Pablo Alderuccio Breakdown of academic impact, for papers by Jordina Rovira Breakdown of academic impact, for papers by Iván Dlouhy Breakdown of academic impact, for papers by Emmanuelle Nicolas‐Virelizier Breakdown of academic impact, for papers by Haiwen Huang Breakdown of academic impact, for papers by Gottfried von Keudell Breakdown of academic impact, for papers by Catherine Chassagne‐Clément Breakdown of academic impact, for papers by Patti Cohen Breakdown of academic impact, for papers by Kaija Vasala
Rankless by CCL
2026